Earnings Preview For Strata Skin Sciences

Strata Skin Sciences SSKN is set to give its latest quarterly earnings report on Thursday, 2025-03-27. Here's what investors need to know before the announcement.

Analysts estimate that Strata Skin Sciences will report an earnings per share (EPS) of $-0.40.

Anticipation surrounds Strata Skin Sciences's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.

New investors should understand that while earnings performance is important, market reactions are often driven by guidance.

Performance in Previous Earnings

In the previous earnings release, the company missed EPS by $0.09, leading to a 7.37% drop in the share price the following trading session.

Here's a look at Strata Skin Sciences's past performance and the resulting price change:

Performance of Strata Skin Sciences Shares

Shares of Strata Skin Sciences were trading at $2.72 as of March 25. Over the last 52-week period, shares are down 31.22%. Given that these returns are generally negative, long-term shareholders are likely a little upset going into this earnings release.

Analyst Opinions on Strata Skin Sciences

Understanding market sentiments and expectations within the industry is crucial for investors. This analysis delves into the latest insights on Strata Skin Sciences.

A total of 1 analyst ratings have been received for Strata Skin Sciences, with the consensus rating being Buy. The average one-year price target stands at $6.0, suggesting a potential 120.59% upside.

Analyzing Ratings Among Peers

In this analysis, we delve into the analyst ratings and average 1-year price targets of and Ekso Bionics Holdings, three key industry players, offering insights into their relative performance expectations and market positioning.

• The prevailing sentiment among analysts is an Buy trajectory for Ekso Bionics Holdings, with an average 1-year price target of $6.33, implying a potential 132.72% upside.

Summary of Peers Analysis

The peer analysis summary outlines pivotal metrics for and Ekso Bionics Holdings, demonstrating their respective standings within the industry and offering valuable insights into their market positions and comparative performance.

Key Takeaway:

Strata Skin Sciences ranks higher in Revenue Growth compared to its peers. However, it lags behind in Gross Profit and Return on Equity. Overall, it is positioned in the middle among its peers based on the provided metrics.

Unveiling the Story Behind Strata Skin Sciences

Strata Skin Sciences Inc is a medical technology company engaged in developing and commercializing products for the treatment of dermatological disorders. Its primary products include the XTRAC excimer laser and VTRAC lamp systems utilized in the treatment of psoriasis, vitiligo and various other skin conditions. Its operating segment includes Dermatology Recurring Procedures which is the key revenue driver and Dermatology Procedures Equipment. The Dermatology Recurring Procedures segment derives its revenues from the usage of its equipment by dermatologists to perform XTRAC procedures. Its Dermatology Procedures Equipment segment generates revenues from the sale of equipment, such as lasers and lamp products. Geographically, it derives a majority of revenue from the United states.

A Deep Dive into Strata Skin Sciences's Financials

Market Capitalization: Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.

Revenue Challenges: Strata Skin Sciences's revenue growth over 3 months faced difficulties. As of 30 September, 2024, the company experienced a decline of approximately -0.62%. This indicates a decrease in top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.

Net Margin: Strata Skin Sciences's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of -24.12%, the company showcases strong profitability and effective cost management.

Return on Equity (ROE): Strata Skin Sciences's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -22.53% ROE, the company effectively utilizes shareholder equity capital.

Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of -5.32%, the company showcases effective utilization of assets.

Debt Management: Strata Skin Sciences's debt-to-equity ratio stands notably higher than the industry average, reaching 1.76. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.

To track all earnings releases for Strata Skin Sciences visit their earnings calendar on our site.

This article was generated by Benzinga's automated content engine and reviewed by an editor.